论文部分内容阅读
目的探讨TIP30在脑胶质瘤中的表达及其临床意义。方法采用免疫组织化学法检测70例脑胶质瘤病人石蜡病理切片中TIP30蛋白表达,并分析其表达与临床病理特征之间的关系;同时,采用RT-PCR方法检测16例脑胶质瘤新鲜组织中TIP30基因的含量。结果 TIP30蛋白在36例(51.4%)脑胶质瘤标本和8例(88.9%)正常脑组织标本中的表达差异有统计学意义(P=0.04)。TIP30的表达与患者的年龄、性别无关,与脑胶质瘤的病理类型、分级和肿瘤大小相关(P<0.05)。单因素分析结果显示,TIP30阳性表达的脑胶质瘤病人总生存时间长于阴性表达组(P=0.003)。RT-PCR结果亦表明,脑胶质瘤中TIP30基因含量低于正常脑组织(P=0.001)。结论 TIP30在脑胶质瘤中表达下调,可能充当抑癌基因的角色,同时也可能是脑胶质瘤病人重要的预后指标之一。
Objective To investigate the expression of TIP30 in glioma and its clinical significance. Methods Immunohistochemistry was used to detect the expression of TIP30 in paraffin-embedded sections of 70 patients with glioma. The relationship between the expression of TIP30 and clinicopathological features was analyzed. Meanwhile, the expression of TIP30 protein in 16 gliomas was detected by RT-PCR. TIP30 gene content in tissues. Results The expression of TIP30 protein in 36 (51.4%) glioma specimens and 8 (88.9%) normal brain tissue samples was significantly different (P = 0.04). The expression of TIP30 was not related to the age and gender of the patients, but also to the pathological types, grading and tumor size of gliomas (P <0.05). Univariate analysis showed that the total survival time of TIP30-positive glioma patients was longer than that of negative expression group (P = 0.003). The results of RT-PCR also showed that the content of TIP30 in glioma was lower than that in normal brain (P = 0.001). Conclusions TIP30 is down-regulated in gliomas and may play a role in tumor suppressor genes. It may also be one of the important prognostic indicators in patients with glioma.